mitoxantrone has been researched along with Colorectal Neoplasms in 20 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These data are consistent with a lack of therapeutic activity of mitoxantrone when administered by hepatic arterial infusion for the treatment of hepatocellular carcinoma or metastatic colorectal cancer." | 9.07 | A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. ( Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993) |
| "We investigated the therapeutic efficiency of sulfonate-modified polyvinyl alcohol beads loaded with doxorubicin, irinotecan or mitoxantrone in vitro and in vivo in a model of experimental peritoneal carcinomatosis (PC)." | 7.75 | Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. ( Faissner, R; Gasimova, L; Keese, M; Lewis, A; Löhr, M; Samel, S; Schwenke, K; Shang, E; Yagublu, V, 2009) |
| "We have recently evaluated the combination of raltitrexed, levofolinic acid (LFA) and 5-fluorouracil (5-FU) in advanced head and neck and colorectal cancer, and we have shown that this combination is well tolerated and has clinical activity." | 5.09 | Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Ionna, F; Rivellini, F, 2001) |
| "These data are consistent with a lack of therapeutic activity of mitoxantrone when administered by hepatic arterial infusion for the treatment of hepatocellular carcinoma or metastatic colorectal cancer." | 5.07 | A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. ( Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993) |
| "CT26 murine colorectal cancer cells were treated with physiologic levels of the potent inducer of immunogenic cell death mitoxantrone (MTX)." | 3.91 | Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases. ( Kunda, NM; Maker, AV; Prabhakar, BS; Qiao, G; Qin, J; Tulla, K, 2019) |
| " To this goal, we exposed colorectal cancer cell lines, genetically modified to express high or low miR-27a levels, to two bona fide ICD inducers (mitoxantrone and oxaliplatin)." | 3.83 | The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells. ( Budillon, A; Colangelo, T; Colantuoni, V; Galgani, M; Matarese, G; Mazzoccoli, G; Milone, MR; Muccillo, L; Polcaro, G; Pucci, B; Sabatino, L; Santopaolo, M; Ziccardi, P, 2016) |
| "We investigated the therapeutic efficiency of sulfonate-modified polyvinyl alcohol beads loaded with doxorubicin, irinotecan or mitoxantrone in vitro and in vivo in a model of experimental peritoneal carcinomatosis (PC)." | 3.75 | Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. ( Faissner, R; Gasimova, L; Keese, M; Lewis, A; Löhr, M; Samel, S; Schwenke, K; Shang, E; Yagublu, V, 2009) |
| "In search of novel mechanisms that may lead to the development of chemoresistance of malignant tumors of the large bowel we used two-dimensional electrophoresis to identify proteins that were overexpressed in colorectal and fibrosarcoma cell lines that were resistant towards mitoxantrone." | 3.70 | Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. ( Dietel, M; Hütter, G; Köttgen, E; Lage, H; Schadendorf, D; Sinha, P, 1999) |
| "Sporadic breast carcinomas demonstrate microsatellite instability, reflecting the presence of DNA mismatch repair-deficient cells, in about one fourth of cases at the time of diagnosis." | 1.31 | Resistance to topoisomerase poisons due to loss of DNA mismatch repair. ( Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H, 2001) |
| "In primary colorectal cancers, the level of MXR7 mRNA expression correlated loosely with the mRNA expression level of the multidrug-resistance-associated protein (MRP)." | 1.30 | Expression of the novel mitoxantrone resistance associated gene MXR7 in colorectal malignancies. ( Dietel, M; Fröschle, G; Lage, H; Reymann, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, KJ | 1 |
| Zhong, HJ | 1 |
| Li, G | 1 |
| Liu, C | 1 |
| Wang, HD | 1 |
| Ma, DL | 1 |
| Leung, CH | 1 |
| Liu, K | 1 |
| Chen, Y | 1 |
| Shi, XB | 1 |
| Xing, ZH | 1 |
| He, ZJ | 1 |
| Wang, ST | 1 |
| Li, YC | 1 |
| Liu, WJ | 1 |
| Zhang, PW | 1 |
| Yu, ZZ | 1 |
| Mo, XM | 1 |
| Shi, XY | 1 |
| Chen, ZS | 1 |
| Shi, Z | 1 |
| Ni, W | 1 |
| Wu, J | 1 |
| Feng, Y | 2 |
| Hu, Y | 1 |
| Liu, H | 1 |
| Chen, J | 1 |
| Chen, F | 1 |
| Tian, H | 1 |
| Zhu, LL | 1 |
| Shi, JJ | 1 |
| Guo, YD | 1 |
| Yang, C | 1 |
| Wang, RL | 1 |
| Li, SS | 1 |
| Gan, DX | 1 |
| Ma, PX | 1 |
| Li, JQ | 1 |
| Su, HC | 1 |
| Ge, C | 1 |
| Wang, Y | 2 |
| Wang, S | 1 |
| Zhang, K | 1 |
| Xu, X | 1 |
| Zhang, Z | 1 |
| Zhao, Y | 1 |
| Gao, L | 1 |
| Dai, F | 1 |
| Xie, S | 1 |
| Wang, C | 1 |
| Qin, J | 1 |
| Kunda, NM | 1 |
| Qiao, G | 1 |
| Tulla, K | 1 |
| Prabhakar, BS | 1 |
| Maker, AV | 1 |
| Colangelo, T | 1 |
| Polcaro, G | 1 |
| Ziccardi, P | 1 |
| Muccillo, L | 1 |
| Galgani, M | 1 |
| Pucci, B | 1 |
| Milone, MR | 1 |
| Budillon, A | 1 |
| Santopaolo, M | 1 |
| Mazzoccoli, G | 1 |
| Matarese, G | 1 |
| Sabatino, L | 1 |
| Colantuoni, V | 1 |
| Keese, M | 1 |
| Gasimova, L | 1 |
| Schwenke, K | 1 |
| Yagublu, V | 1 |
| Shang, E | 1 |
| Faissner, R | 1 |
| Lewis, A | 1 |
| Samel, S | 1 |
| Löhr, M | 1 |
| Toh, YM | 1 |
| Li, TK | 1 |
| Kyle, AH | 1 |
| Huxham, LA | 1 |
| Chiam, AS | 1 |
| Sim, DH | 1 |
| Minchinton, AI | 1 |
| Jones, DV | 1 |
| Patt, YZ | 1 |
| Ajani, JA | 1 |
| Abbruzzese, J | 1 |
| Carrasco, CH | 1 |
| Charnsangavej, C | 1 |
| Levin, B | 1 |
| Wallace, S | 1 |
| Kornmann, M | 4 |
| Link, KH | 4 |
| Lenz, HJ | 1 |
| Pillasch, J | 3 |
| Metzger, R | 1 |
| Butzer, U | 1 |
| Leder, GH | 2 |
| Weindel, M | 1 |
| Safi, F | 1 |
| Danenberg, KD | 1 |
| Beger, HG | 3 |
| Danenberg, PV | 2 |
| Lage, H | 2 |
| Dietel, M | 2 |
| Fröschle, G | 1 |
| Reymann, A | 1 |
| Leder, G | 2 |
| Pillasch, AF | 1 |
| Sunelaitis, E | 2 |
| Schatz, M | 2 |
| Pressmar, J | 1 |
| Sinha, P | 1 |
| Hütter, G | 1 |
| Köttgen, E | 1 |
| Schadendorf, D | 1 |
| Caponigro, F | 1 |
| Avallone, A | 1 |
| Rivellini, F | 1 |
| Comella, P | 2 |
| Ionna, F | 1 |
| De Rosa, V | 1 |
| Comella, G | 2 |
| Fedier, A | 1 |
| Schwarz, VA | 1 |
| Walt, H | 1 |
| Carpini, RD | 1 |
| Haller, U | 1 |
| Fink, D | 1 |
| Gansauge, F | 1 |
| Formentini, A | 1 |
| Staib, L | 1 |
| Casaretti, R | 1 |
| Daponte, A | 1 |
| Parziale, A | 1 |
| Iervolino, V | 1 |
| Santillo, G | 1 |
| Zarrilli, D | 1 |
1 review available for mitoxantrone and Colorectal Neoplasms
| Article | Year |
|---|---|
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1999 |
4 trials available for mitoxantrone and Colorectal Neoplasms
| Article | Year |
|---|---|
A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver.
Topics: Adult; Aged; Carcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Female; Hepatic Artery; Hum | 1993 |
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 1997 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
15 other studies available for mitoxantrone and Colorectal Neoplasms
| Article | Year |
|---|---|
Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
Topics: Adenocarcinoma; Apoptosis; Caco-2 Cells; Cell Line; Colorectal Neoplasms; Dose-Response Relationship | 2018 |
Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Co | 2022 |
Metformin reprograms tumor microenvironment and boosts chemoimmunotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Humans; Hyaluronic Acid; Immunotherap | 2022 |
NUCKS1 promotes the progression of colorectal cancer via activating PI3K/AKT/mTOR signaling pathway.
Topics: Colorectal Neoplasms; Humans; Mitoxantrone; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosph | 2023 |
Suppression of oxidative phosphorylation and IDH2 sensitizes colorectal cancer to a naphthalimide derivative and mitoxantrone.
Topics: Animals; Antioxidants; Autophagy; Cell Death; Cell Line, Tumor; Citric Acid Cycle; Colorectal Neopla | 2021 |
Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Cell Cycle Checkpoints; Cell Line, Tumor; Colorecta | 2019 |
The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Calreticulin; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell P | 2016 |
Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Chemoembolization, Therap | 2009 |
Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type II; Gene Kno | 2011 |
Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Colorectal Neoplasms; Daunorubicin; Doxorubicin; Epirub | 2004 |
Expression of the novel mitoxantrone resistance associated gene MXR7 in colorectal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP-Binding Cassette Transporters; Colorectal | 1998 |
Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Di | 1999 |
Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, | 2001 |
Treatment of advanced colorectal cancer with mitoxantrone, high dose folinic acid and fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1991 |